Drugs / hAd5-S-Fusion+N-ETSD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04732468 | Feb 2021 → Jul 2022 | COVID-19 | ImmunityBio, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hAd5-SFusion+ N-ETSD | “Drug: hAd5-SFusion+ N-ETSD (Oral capsule)” NCT04732468 ↗ |
| Known as | hAd5-S-Fusion+N-ETSD Vaccine | “The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and...” NCT04732468 ↗ |
| Modality | Vaccine | “The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and...” NCT04732468 ↗ |
| Route | Oral | “Subcutaneously and Orally Administered Prophylactic Vaccination” NCT04732468 ↗ |
| Route | Subcutaneous | “Subcutaneously and Orally Administered Prophylactic Vaccination” NCT04732468 ↗ |